BRAIN BIOTECNA O.N. overview

EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG 18.03.2025 / 16:45 CET/CEST The issuer is solely responsible for the content of this announcement. Results of the 2025 Annual General Meeting for the 2023/24 financial year of BRAIN Biotech AG ZWINGENBERG, March 18, 2025 – At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949),...

EQS-News: BRAIN Biotech AG / Key word(s): Quarterly / Interim Statement BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division 26.02.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAINBiocatalysts organic growth at 11 % in Q1 Quantitative guidance looking at strong...

EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative 13.02.2025 / 09:14 CET/CEST The issuer is solely responsible for the content of this announcement. Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative Development of BioXtractor V2 pilot by BRAIN and PX Group and production of first BioGold nuggets from a local waste stream...

EQS-News: BRAIN Biotech AG / Key word(s): Annual Report/Annual Results Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects 15.01.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects Group cash and cash equivalents improved to € 27.2 million Successfully closed two milestone...

EQS-News: BRAIN Biotech AG / Key word(s): Capital Markets Day BRAIN Biotech AG Sharpens Focus on Profitable Growth 12.12.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG Sharpens Focus on Profitable Growth Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D...

EQS-News: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology 31.10.2024 / 19:20 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E ® CRISPR-Cas technology Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise...

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties 31-Oct-2024 / 19:11 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR...

EQS-News: BRAIN Biotech AG / Key word(s): Personnel Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons 03.10.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of...